West Pharmaceutical Services, Inc. (WST)
Reasons to Add West Pharmaceutical Stock to Your Portfolio Right Now
WST eyes growth from high-value components, GLP-1 drug demand and Annex 1 conversions, but generics destocking and European capacity constraints pose risks.
Why West Pharmaceutical Services (WST) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wall Street Analysts Think West Pharmaceutical (WST) Could Surge 32.33%: Read This Before Placing a Bet
The mean of analysts' price targets for West Pharmaceutical (WST) points to a 32.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why West Pharmaceutical Services (WST) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
West Pharmaceutical's Under-the-Radar Dividend Worth Watching
West Pharmaceutical Services just sent investors $0.22 per share on February 4, 2026, marking the company's latest quarterly dividend payment.
West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call Transcript
West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call Transcript
WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up
West Pharmaceutical beats Q4 EPS and revenue estimates as proprietary products drive growth, while shares jump nearly 3.6% premarket on upbeat 2026 outlook.
West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
West Pharmaceutical Services (WST) Tops Q4 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $1.82 per share a year ago.
WST Q4 Earnings Preview: Can HVP Momentum Continue to Drive Margins?
West Pharmaceutical heads into Q4 with HVP demand likely lifting margins, but tariff risk looms as revenue and EPS targets come into focus.
West Pharmaceutical Services, Inc. (WST) Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity Transcript
West Pharmaceutical Services, Inc. (WST) Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity Transcript
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
